Tagged with Denmark

Denmark As Denmark prepares to assume the rotating presidency of the Council of the European Union on July 1st of 2025, attention is turning to what this small yet strategically positioned country will bring to the table. Under the slogan ‘A strong Europe in a changing world’, the Danish Ministry of…

Denmark Vanessa Vega Saenz discusses Denmark’s strategic approach to attracting foreign investments in life sciences, highlighting the country’s strengths in clinical trials, production, and health data access. Supported by a robust regulatory framework, strong public-private collaboration, and a clear national vision, Denmark is both a competitive European hub and a trusted…

Denmark As Denmark sets its sights on becoming a global leader in life sciences by 2030, Morten Bødskov, Minister for Industry, Business, and Financial Affairs, outlines the strategic pillars of the country’s Life Science Strategy Toward 2030. With an unwavering commitment to strengthening Denmark’s competitive edge in the face of fierce…

Denmark Steve Wright, General Manager of Boehringer Ingelheim Denmark and Norway, shares insights on how the company is advancing its ambitious pipeline and aligning with Denmark’s national healthcare priorities. In this interview, Wright discusses Boehringer Ingelheim’s strategic focus on innovation, access, and prevention, while reflecting on the company’s evolving role in…

Denmark Curiosity has been the driving force behind Montse Jansà’s journey, a curiosity not only for science, but for the people, processes, and decisions that bring innovation to life. From a foundation in biology and clinical research to leadership roles across Europe, she has consistently sought opportunities to create meaningful impact.…

Denmark Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is guiding the century-old company through a bold transformation, restoring profitability, embracing external innovation, and laying the groundwork for a potential…

Denmark Marianne Pilgaard discusses the evolution of Denmark’s clinical trial landscape, the continued top-tier status of the country in trial activity per capita, and the nation’s commitment to digital innovation and patient-centric research. Pilgaard covers the impact of healthcare reform, regulatory harmonisation, decentralised trials, and the prospects for advanced therapies and…

Denmark Jakob Nielsen, CEO of Healthcare Denmark, discusses how Denmark has strengthened its role in global health diplomacy and life sciences since 2021. Nielsen highlights the country’s focus on strategic international partnerships, digitalisation, and patient-centric healthcare reform, positioning Denmark as a transparent and collaborative partner in addressing shared healthcare challenges. What…

Denmark Already one of Europe’s top countries for clinical trials per capita, Denmark has further strengthened its position in recent years. The number of active trials in the country rose from 410 in 2022 to 450 in 2023, backed by increasing citizen participation and a healthcare ecosystem built on trusted health…

Denmark Peter Jorgensen, Director of the Danish Generic and Biosimilar Medicines Industry Association, discusses Denmark’s robust framework for generics and biosimilars, offering insight into a system that has delivered high penetration, cost savings, and broad public trust. From legal structures and patient attitudes to incentives and hospital adoption, Jorgensen outlines why…

Denmark As Denmark launches its ambitious Life Science Strategy 2030, the Danish Medicines Agency (DKMA), long held as the embodiment of European regulatory excellence, is fine-tuning its priorities. New director Nils Falk Bjerregaard sees the DKMA’s role as a “facilitator of innovation,” supporting early-stage development and leveraging real-world data at home,…

Denmark Peter Halling, CEO of ALK, leads the century-old allergy immunotherapy innovator through a transformative phase focused on expanding patient access and innovation globally. In this interview, Halling discusses ALK’s Allergy+ growth strategy and response to rising allergy prevalence, unique “field to pharmacy” production model, and ambitions to balance strong European…